Retatrutide cuts A1C and weight in first Phase 3 diabetes trial
Eli Lilly says the triple agonist met endpoints in type 2 diabetes, its first Phase 3 readout in that indication.
PR
By Priya Raman · Science Reporter
Mar 19 03:00 ETSource: Eli Lilly
The wire
- 01Lilly announced that retatrutide, its GIP/GLP-1/glucagon triple agonist, produced significant reductions in A1C and body weight in its first Phase 3 type 2 diabetes trial.
- 02A third incretin mechanism entering late-stage diabetes data expands the pipeline beyond semaglutide and tirzepatide for clinicians tracking sequencing and access.
- 03Full efficacy, safety and tolerability numbers are pending presentation or publication; the announcement is company-reported topline.
From the source
Read at investor.lilly.comLilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes